thalidomide has been researched along with Castleman Disease in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Castleman Disease: Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 5.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria." | 2.61 | POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. ( Dispenzieri, A, 2019) |
| "Castlemans disease is the term for reactive lymphocytary and plasmocytary proliferation which occurs in the unicentric (localized) form, usually without systemic symptoms, or in the generalized/multicentric form, typically with systemic symptoms (www." | 2.53 | [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature]. ( Adam, Z; Čermáková, Z; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Michalková, E; Penka, I; Petrášová, H; Pour, L; Pourová, E; Řehák, Z; Sandecká, V; Ševčíková, S; Sokol, F; Szturz, P; Volfová, P, 2016) |
| "POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes." | 2.49 | New advances in the diagnosis and treatment of POEMS syndrome. ( Li, J; Zhou, DB, 2013) |
| "Systematic search for monoclonal gammopathy by immunofixation and serum free light chains is very useful for the management of progressive peripheral neuropathies of unknown origin." | 2.47 | [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. ( Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M, 2011) |
| "Castlemans disease (also called angiofollicular lymph node hyperplasia) can take two forms with different prognosis: the localized form can usually be treated by a surgical intervention and has therefore a favourable prognosis." | 1.39 | [PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview]. ( Adam, Z; Cervinková, I; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Penka, I; Pour, L; Rehák, Z; Storková, T; Svoboda, T; Szturz, P, 2013) |
| "Castleman disease is a rare lymphoproliferative disorder." | 1.35 | Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. ( Gonda, A; Illes, A; Miltenyi, Z; Remenyik, E; Tar, I; Toth, J, 2009) |
| "Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology." | 1.32 | Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. ( Lee, FC; Merchant, SH, 2003) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 1.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Lomas, OC | 1 |
| Streetly, M | 1 |
| Pratt, G | 1 |
| Cavet, J | 1 |
| Royston, D | 1 |
| Schey, S | 2 |
| Ramasamy, K | 2 |
| Zhou, X | 1 |
| Wei, J | 1 |
| Lou, Y | 1 |
| Xu, G | 1 |
| Yang, M | 1 |
| Liu, H | 1 |
| Mao, L | 1 |
| Tong, H | 1 |
| Jin, J | 1 |
| van Rhee, F | 1 |
| Stone, K | 1 |
| Dispenzieri, A | 1 |
| Adam, Z | 4 |
| Szturz, P | 4 |
| Křen, L | 2 |
| Krejčí, M | 4 |
| Pour, L | 4 |
| Svoboda, T | 1 |
| Hanke, I | 2 |
| Penka, I | 2 |
| Koukalová, R | 4 |
| Rehák, Z | 4 |
| Cervinková, I | 1 |
| Storková, T | 1 |
| Král, Z | 3 |
| Mayer, J | 4 |
| Lin, Q | 1 |
| Fang, B | 1 |
| Huang, H | 1 |
| Yu, F | 1 |
| Chai, X | 1 |
| Zhang, Y | 1 |
| Zhou, J | 1 |
| Xia, Q | 1 |
| Li, Y | 1 |
| Song, Y | 1 |
| Michalková, E | 1 |
| Pourová, E | 1 |
| Volfová, P | 1 |
| Sandecká, V | 1 |
| Čermáková, Z | 1 |
| Sokol, F | 1 |
| Petrášová, H | 1 |
| Ševčíková, S | 1 |
| Stary, G | 1 |
| Kohrgruber, N | 1 |
| Herneth, AM | 1 |
| Gaiger, A | 1 |
| Stingl, G | 1 |
| Rieger, A | 1 |
| Miltenyi, Z | 1 |
| Toth, J | 1 |
| Gonda, A | 1 |
| Tar, I | 1 |
| Remenyik, E | 1 |
| Illes, A | 1 |
| Adams, D | 1 |
| Lozeron, P | 1 |
| Theaudin, M | 1 |
| Ribrag, V | 1 |
| Bourhis, JH | 1 |
| Lacroix, C | 1 |
| Zhao, X | 1 |
| Shi, R | 1 |
| Jin, X | 1 |
| Zheng, J | 1 |
| Wang, X | 1 |
| Ye, S | 1 |
| Xiong, C | 1 |
| Gao, J | 1 |
| Xiao, C | 1 |
| Xing, X | 1 |
| Chovancová, J | 1 |
| Stehlíková, O | 1 |
| Klabusay, M | 1 |
| Zahradová, L | 2 |
| Hájek, R | 2 |
| Briani, C | 1 |
| Manara, R | 1 |
| Lessi, F | 1 |
| Citton, V | 1 |
| Zambello, R | 1 |
| Adami, F | 1 |
| Gandhi, S | 1 |
| Tenant-Flowers, M | 1 |
| Ceesay, M | 1 |
| Corderoy, S | 1 |
| Marcus, R | 1 |
| Nebeský, T | 1 |
| Li, J | 1 |
| Zhou, DB | 1 |
| Lee, FC | 2 |
| Merchant, SH | 1 |
| Jung, CP | 1 |
| Emmerich, B | 1 |
| Goebel, FD | 1 |
| Bogner, JR | 1 |
| Menegato, MA | 1 |
| Canelles, MF | 1 |
| Tonutti, E | 1 |
| Pizzolitto, S | 1 |
| Starkey, CR | 1 |
| Joste, NE | 1 |
| Kim, SY | 1 |
| Lee, SA | 1 |
| Ryoo, HM | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Bae, SH | 1 |
5 reviews available for thalidomide and Castleman Disease
| Article | Year |
|---|---|
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
Topics: Adrenal Cortex Hormones; Allografts; Bortezomib; Castleman Disease; Diagnosis, Differential; Humans; | 2019 |
[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Castleman Disease; Drug Therapy, Combination; | 2016 |
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Dru | 2011 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromo | 2013 |
17 other studies available for thalidomide and Castleman Disease
| Article | Year |
|---|---|
The management of Castleman disease.
Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Combined Che | 2021 |
Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
Topics: Adult; Castleman Disease; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans | 2017 |
Storming the Castle with TCP.
Topics: Castleman Disease; Cyclophosphamide; Humans; Prednisone; Thalidomide; Thyroid Neoplasms | 2019 |
[PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview].
Topics: Castleman Disease; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Huma | 2013 |
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Dis | 2015 |
Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; HIV Infections; H | 2008 |
Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
Topics: Adrenal Cortex Hormones; Castleman Disease; Cyclosporine; Female; Humans; Immunomodulation; Immunosu | 2009 |
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases.
Topics: Adult; Biopsy, Needle; Castleman Disease; Diagnosis, Differential; Drug Therapy, Combination; Female | 2011 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combinat | 2011 |
Lenalidomide: a new treatment option for Castleman disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Humans; Le | 2012 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; | 2012 |
Rituximab and thalidomide combination therapy for Castleman disease.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; Drug Therapy, Combination; Female; | 2012 |
Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Topics: Adult; Anemia; Antibodies, Viral; Axilla; Biopsy; Castleman Disease; Cytokines; Female; Herpesvirus | 2003 |
Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Castleman Disease; HIV Infections; Humans; Immunosuppressive Agents; | 2004 |
Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
Topics: Aged; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferative; Humans; Immunosu | 2004 |
Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Biopsy; Castleman Disease; Female; Humans; Lymph Nodes; Remission Induction | 2006 |
Thalidomide for POEMS syndrome.
Topics: Adult; Anti-Inflammatory Agents; Castleman Disease; Dexamethasone; Female; Humans; Immunosuppressive | 2006 |